Trials / Active Not Recruiting
Active Not RecruitingNCT03470922
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
- Status
- Active Not Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 714 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Relatlimab | Specified dose on specified day |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2018-04-11
- Primary completion
- 2021-01-25
- Completion
- 2030-12-15
- First posted
- 2018-03-20
- Last updated
- 2025-09-09
- Results posted
- 2022-03-29
Locations
127 sites across 25 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Norway, Poland, Romania, Russia, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03470922. Inclusion in this directory is not an endorsement.